-
The study, which was conducted in collaboration with Stanford University, appeared in the Journal of the American Medical Association.
-
The team, which includes Australian Nobel laureate Professor Peter Doherty, also has scientists from the UK, the US, China, Canada, New Zealand. The study was released on open-access repository Zenodo
-
Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India
-
If there is a SARS-CoV-2 mutant that has the ability to escape immunity, then the size of the third wave could be significant, suggests the study
-
Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.
-
Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.
-
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India
-
China earlier this month, authorised the emergency use of CoronaVac, for children aged between 3 and 17 years.
-
Even 15 weeks after the first dose, eight of 10 people still had detectable germinal centers containing B cells targeting the virus.
-
Scientists are worried about the Delta plus variant due to the presence of Beta variant and the features of the Delta variant in it, which can make it more infectious
-
Now, researchers at Washington University School of Medicine in St. Louis have found that a single mutation gives SARS-CoV-2 the ability to enter cells through another route - one that does not require ACE2.
-
While the new Covid vaccine policy came into effect across the country, TS perhaps remains the only State that has adopted a measured, practical, and logical approach of vaccinating individuals who need them the most
-
The research was presented at the World Microbe Forum, an online meeting of the American Society for Microbiology (ASM), the Federation of European Microbiological Societies (FEMS), and several other societies that will take place online June 20-24.
-
The study, published on Thursday in the journal JAMA, recruited 45 healthy male volunteers aged 18 to 50 years scheduled for mRNA COVID-19 vaccination by Pfizer-BioNTech and Moderna.
-
The research team has observed that around 68 per cent of the S-proteins exist in open formation at physiological pH 7.4, but their proportion decreases when the pH is slightly higher (pH 8.0) or lower (pH 6.5).
-
Experts say continued circulation of coronavirus, threat from new emerging variants create possibility
-
A compound found in green tea called gallocatechin may help in the development of a drug that can combat the SARS-CoV-2.
-
Lockdown not only helped break Covid transmission but also has gone a long way in keeping seasonal ailments at bay
-
Lower antibody count after jab does not mean poor immunity, say experts
-
Experts say it can turn into an endemic that causes cold during winter when conditions are favourable for its transmission